Online ISSN: 2515-8260

Keywords : Hepatitis


Prevalence of psychiatric disorders in patients with hepatitis C infection

Dr.(Maj.) Rakesh Saxena, Dr Mahendra Singh

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 3, Pages 2051-2054

Background: HCV is often accompanied by significant medical and psychiatric co-morbidities that can
complicate the course of illness. Some of the more common co-occurring disorders that have received
empirical attention include depression, substance use disorders (SUDs), and chronic pain.Aim of the
study: To study prevalence of psychiatric disorders in patients with hepatitis C infection. Materials and
methods: The present study was conducted in the Department of Psychiatry in the Medical Institute. For
the study, we selected patients whose blood work was positive for antibody to HCV and have the
presence of HCV RNA confirmed by the use of PCR. A total of 50 patients were selected for the study.
For the evaluation of psychiatric disorders in the patients, the patients were given a questionnaire to
complete. Results: A total of 50 subjects were included in the study. 35 subjects were male and 15
subjects were female. Mean age of the patients was 46.23 years. We observed that 9 patients had bipolar
disorder, 15 patients had schizophrenic psychosis, heavy alcohol use was seen in 21 patients, PTSD was
seen in 14 patients, substance use was observed in 19 patients and depression was seen in 33 patients.
Conclusion: Within the limitations of the present study, it can be concluded that patients with hepatitis C
infection have high prevalence of psychiatric disorders, the most common psychiatric disorders in
hepatitis C patients are depression and heavy alcohol use. The quality of life of the patients are
significantly affected by the psychiatric disorders.

HBV Genotyping distribution among Iraqi patients in Wasit Province

Sabreen Hadi Hanash; Kareem Hamed Ghali; Ahmed Darwish Jabbar

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 2, Pages 4263-4278

Hepatitis B viruses are one of the world's most important issues for public health. HBV production is driven by this high mutation rate which results in a high degree of genetic heterogeneity with a distinct geographic distribution of 10 resulting genotypes (A – J) .This study aimed to determination the HBV genotypes distribution among Iraqi hepatitis B virus patients.The study included 100 patientswith positive HBs Ag .Muliplex PCR results showed thatthe percentage of HBV genotypes distributed among patients was as follows: AE 1%, ACD 1% , ABCDEF 1% , ABCDFG 1% , B pure 30%, BC 9% , BD 1%, BE 3% , BF 1%, BCE 6% , BCDE 1%, BCDF 1%, BCEF 1%, C pure 16%, CD 13%, CE7%, CDE 2%, D pure 4%, E pure 1%, so the most common genotype is B pure genotype (30%) , and in the second rank C genotype (16%), however the C mixture genotype was (59%) was common followed by B genotype (55%) .Based on our knowledge this study is the first study in Iraq that documented genotype G in one sample.

Choleretic Activity Of Rutana At Therapeutic Application In Rats With Heliotrin Hepatitis

Boboyevarano Raximovna; Mavlonovanvar Axmadovich; Jurayevagulrux Bafoyevna

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 3, Pages 5188-5193

The experiment established a high hepatoprotective and choleretic activity of Rutan polyphenol isolated from the tannin-bearing plant Rhuscoriaria L. in heliotrinic hepatitis. It is believed that Rutan can be recommended in practical medicine as a means of pathogenetic treatment of hepatitis of various etiologies, including infectious toxic pathologies of the hepatopancreatobiliary system

Hepatoprotective potential of Pterocarpus santalinus mediated biogenic silver nanoparticles against induced hepatitis in male albino rats

Ravi Kumar Nulakachandanam, ShanmugamBasha, Ganesh Babu D, Bharath Kumar Bukkapatnam, VasaviKapuluru, Rajasekhar Maram

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 5, Pages 1998-2007

Hepatitis infection burdens have been increasing and alarming around the globe in recent
years. The mainstream therapeutics of hepatitis infections are non-specific with numerous
side effects. To combat viral hepatitis, a novel therapeutic platform is needed. In the present
study, we explored a novel biogenic approach of nanotechnology as an alternative therapeutic
platform for treating hepatitis. Biogenic silver nanoparticles (PTNPs) synthesised from
Pterocarpus santalinus bark extract were used in the treatment against induced hepatitis. DGalactosamine
was given to male Wistar strain rats to induce hepatitis similar to viral
hepatitis inflammations. The hepatic serum markers, Alanine aminotransferase and Aspartate
aminotransferase were examined during the hepatitis conditions. The results obtained
indicated that the Alanine aminotransferase and Aspartate aminotransferase enzyme levels
were significantly reduced after the treatment with PTNPs. The hepatoprotective activity
demonstrated from PTNPs would find application in alternate therapeutics in the treatment of
hepatitis